Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions

Table 1 The European LeukemiaNet Standardized Reporting System for risk stratification of acute myeloid leukemia based on cytogenetics and molecular testing¹

Risk category	Cytogenetic abnormalities	Molecular abnormalities
Favorable risk	t(15;17) inv(16)/t(16;16)2t(8;21)2	CN-AML with biallelic CEBPA mutationCN-AML with NPM1 mutated but FLT3-ITD negative
Intermediate risk	CN-AMLt(9;11)All others abnormalities not classified as favorable or adverse risk	CN-AML with:NPM1 mutated/FLT3-ITD positiveNPM1 wild type/FLT3-ITD negativet(8;21)/inv (16) with c-KIT mutation
Adverse risk	inv (3)/t(3;3)	CN-AML with FLT3-ITD positive
	t(6;9)
	t(v;11)/MLL rearranged
	- 5/-5q
	-7
	Monosomal karyotype
	Abnormal 17p
	Complex cytogenetics

¹Table modified from Mrózek et al[24];

²The good prognosis of inv(16) and t(8;21) is maintained even with additional cytogenetic abnormalities. The presence of concomitant c-KIT mutation may increase relapse risk in t(8;21) and to lesser extend inv(16). CN-AML: Cytogenetically normal acute myeloid leukemia; CEBPA: CCAAT enhancer binding protein alpha; FLT3-ITD: FMS-like tyrosine kinase 3 gene-internal tandem duplication; MLL: Mixed lineage leukemia; NPM: Nucleophosmin.